The quarterly results present a tale of two narratives. On the surface, operating margins surged to 13.74% in Q4 FY26 from 8.31% in the previous quarter, representing the highest quarterly margin in recent years. Revenue growth of 14.46% quarter-on-quarter and 19.11% year-on-year appears encouraging. Yet beneath this veneer lies a troubling reality: the company's five-year sales growth stands at a meagre 0.60%, whilst operating profit has contracted at a compound annual rate of 12.16% over the same period.
The market's harsh verdict is reflected in the stock's technical positioning. Trading at ₹268.30 as of May 29, 2026, Everest Organics shares have shed 49.98% from their 52-week high of ₹536.40, whilst sitting 36.19% above the 52-week low of ₹197.00. The stock currently trades below all major moving averages, with the 200-day moving average at ₹369.82 serving as a stark reminder of the distance fallen.
Financial Performance: Quarterly Uptick Against Annual Decline
In Q4 FY26, Everest Organics reported net sales of ₹48.75 crores, representing sequential growth of 14.46% from ₹42.59 crores in Q3 FY26 and year-on-year expansion of 19.11% from ₹40.93 crores in Q4 FY25. Operating profit before depreciation, interest, tax, and other income climbed to ₹6.70 crores, yielding an operating margin of 13.74%—a substantial improvement from 8.31% in the preceding quarter and 8.38% a year earlier.
| Quarter | Revenue (₹ Cr) | QoQ % | Operating Margin | Net Profit (₹ Cr) | PAT Margin |
|---|---|---|---|---|---|
| Mar'26 | 48.75 | +14.46% | 13.74% | 2.63 | 5.39% |
| Dec'25 | 42.59 | -16.49% | 8.31% | 0.36 | 0.85% |
| Sep'25 | 51.00 | -5.22% | 10.06% | 1.16 | 2.27% |
| Jun'25 | 53.81 | +31.47% | 8.25% | 1.41 | 2.62% |
| Mar'25 | 40.93 | -2.66% | 8.38% | 2.91 | 7.11% |
| Dec'24 | 42.05 | -4.54% | 9.56% | 1.14 | 2.71% |
| Sep'24 | 44.05 | — | 7.79% | 0.74 | 1.68% |
Net profit of ₹2.63 crores in Q4 FY26 represented a dramatic turnaround from the ₹0.36 crores reported in Q3 FY26, though it fell 9.62% short of the ₹2.91 crores achieved in Q4 FY25. The profit after tax margin stood at 5.39%, recovering from the dismal 0.85% recorded in the previous quarter but still below the 7.11% margin of a year ago. Notably, the company benefited from a negative tax charge of ₹0.46 crores, effectively a tax credit, which flattered the bottom line.
However, the annual picture reveals persistent challenges. For FY25, Everest Organics reported net sales of ₹159.00 crores, down 19.30% from ₹197.00 crores in FY24. The company slipped into a loss of ₹1.00 crore for the full year, compared to breakeven performance in FY24. Operating margins compressed to 4.40% from 5.10% in the prior year, highlighting structural pressures on profitability.
Operational Challenges: Weak Returns and Elevated Leverage
The company's operational efficiency metrics paint a concerning picture. Return on equity stands at just 8.05% for the latest period, whilst the average ROE over recent years languishes at 5.58%—well below the double-digit returns expected from healthy pharmaceutical companies. Return on capital employed fares even worse at 9.06% for the latest period, with a historical average of merely 1.12%, indicating poor capital allocation and weak profitability relative to the capital base.
Everest Organics carries a debt-to-equity ratio of 0.67, which whilst not excessive in absolute terms, becomes problematic when viewed alongside anaemic returns. The company's debt-to-EBITDA ratio averages a concerning 15.01 times, suggesting the business generates insufficient cash flow to comfortably service its debt obligations. The EBIT-to-interest coverage ratio averages just 0.75 times, meaning operating profits fail to cover interest expenses—a red flag for financial sustainability.
Critical Concern: Inadequate Interest Coverage
In Q4 FY26, interest costs surged to ₹2.76 crores, the highest quarterly burden in recent periods. Operating profit to interest coverage stood at just 2.43 times for the quarter—the lowest ratio observed. This deteriorating coverage raises questions about the company's ability to sustain debt servicing as interest rates remain elevated and operational performance remains volatile.
The balance sheet reveals further stress. Trade payables stood at ₹95.79 crores as of March 2026, down from ₹110.65 crores a year earlier, suggesting some working capital normalisation. However, fixed assets of ₹49.60 crores against shareholder funds of ₹69.95 crores indicate limited financial flexibility. Current assets of ₹147.90 crores provide some cushion against current liabilities of ₹139.92 crores, but the tight working capital position leaves little room for operational disruptions.
The Growth Conundrum: Stagnation Amid Industry Expansion
Perhaps the most troubling aspect of Everest Organics' investment case is its complete absence of meaningful growth. Over the past five years, sales have expanded at a compound annual rate of just 0.60%—essentially flat in an industry that has witnessed robust expansion. Operating profit (EBIT) has actually contracted at 12.16% annually over the same period, reflecting margin compression and operational challenges.
This growth paralysis stands in stark contrast to the broader pharmaceuticals and biotechnology sector, which has delivered 9.25% returns over the past year whilst Everest Organics shares have plummeted 38.88%. The company's underperformance of 48.13 percentage points versus its sector peers underscores fundamental weakness rather than temporary market dislocation.
Quality Assessment: Below Average Fundamentals
The company carries a "Below Average" quality grade based on long-term financial performance. With five-year sales growth of 0.60%, EBIT contraction of 12.16% annually, weak ROCE of 1.12%, and elevated debt-to-EBITDA of 15.01 times, Everest Organics lacks the fundamental strength typically associated with quality pharmaceutical manufacturers. The absence of institutional interest—with just 0.02% institutional holdings—further validates concerns about the company's investment merit.
Industry Context: Lagging the Pharmaceutical Recovery
The Indian pharmaceutical sector has demonstrated resilience, with many active pharmaceutical ingredient manufacturers benefiting from global supply chain diversification away from China and robust domestic demand. However, Everest Organics has failed to capitalise on these tailwinds. Whilst peer companies have expanded capacity, secured new contracts, and improved margins, Everest Organics has struggled with volatile quarterly performance and declining annual revenues.
The company's product portfolio focuses on bulk drugs and intermediaries, a segment characterised by intense competition and pricing pressure. Without differentiated products, strong research and development capabilities, or significant scale advantages, Everest Organics finds itself competing primarily on price—a strategy that has evidently failed to generate sustainable profitability or growth.
Peer Comparison: Valuation Premium Without Justification
A comparison with pharmaceutical sector peers reveals Everest Organics trading at an unjustified valuation premium despite inferior fundamentals. The company's price-to-earnings ratio of 44.53 times significantly exceeds the sector average, whilst its return on equity of 5.58% trails most comparable companies.
| Company | P/E Ratio | ROE % | Debt to Equity | Price to Book |
|---|---|---|---|---|
| Everest Organics | 44.53 | 5.58% | 0.67 | 3.59 |
| Trident Lifeline | 15.27 | 18.02% | 0.70 | 2.95 |
| Gennex Lab. | 16.36 | 9.64% | 0.19 | 1.35 |
| Transchem | 63.92 | 4.56% | -0.01 | 3.39 |
| Ambalal Sarabhai | 14.76 | 16.85% | 0.23 | 1.72 |
Trident Lifeline, for instance, trades at just 15.27 times earnings whilst delivering an ROE of 18.02%—more than triple Everest Organics' return. Gennex Laboratories commands a P/E of 16.36 with an ROE of 9.64%, still superior to Everest Organics despite a lower valuation multiple. Even Ambalal Sarabhai, with an ROE of 16.85%, trades at a P/E of 14.76, less than a third of Everest Organics' multiple.
The price-to-book ratio of 3.59 times for Everest Organics appears particularly stretched given the company's weak return profile. Investors are paying significantly more than three times book value for a business that generates single-digit returns on equity—a clear valuation disconnect that suggests substantial downside risk.
Valuation Analysis: Expensive Relative to Fundamentals
Despite the significant share price decline over the past year, Everest Organics remains expensively valued relative to its operational performance. The P/E ratio of 44.53 times stands well above the industry average of 34 times, whilst the company's growth and profitability metrics lag peers substantially. The EV-to-EBITDA multiple of 18.65 times appears elevated for a business with stagnant sales and contracting operating profits.
The company's valuation grade has deteriorated over recent quarters, moving from "Very Attractive" in July 2024 to "Risky" by February 2025, and currently sits at "Expensive" as of May 2026. This progression reflects both share price volatility and deteriorating fundamentals. The PEG ratio of 0.21, whilst superficially attractive, is rendered meaningless by the company's negative five-year EBIT growth rate.
A fair value assessment based on peer multiples and the company's weak return profile suggests significant downside risk from current levels. Applying a 25 times P/E multiple—generous given the company's quality issues—to normalised earnings of approximately ₹4.00 crores annually yields a market capitalisation of ₹100.00 crores, implying a fair value of approximately ₹125.00 per share, representing 53% downside from the current price of ₹268.30.
Shareholding Pattern: Promoter Dilution and Institutional Absence
The shareholding pattern reveals concerning trends. Promoter holdings have declined from 61.09% in March 2025 to 59.58% in March 2026, representing a cumulative reduction of 151 basis points over four quarters. Whilst the dilution appears modest, the consistent quarterly reduction raises questions about promoter confidence in the business outlook.
| Quarter | Promoter % | QoQ Change | FII % | MF % | Non-Inst % |
|---|---|---|---|---|---|
| Mar'26 | 59.58% | -0.03% | 0.00% | 0.00% | 40.40% |
| Dec'25 | 59.61% | -0.03% | 0.00% | 0.00% | 40.37% |
| Sep'25 | 59.64% | -1.35% | 0.00% | 0.00% | 40.33% |
| Jun'25 | 60.99% | -0.10% | 0.00% | 0.00% | 38.98% |
| Mar'25 | 61.09% | — | 0.00% | 0.00% | 38.89% |
More concerning is the complete absence of institutional interest. Foreign institutional investors, mutual funds, and insurance companies hold zero stakes in Everest Organics. Other domestic institutional investors maintain a negligible 0.02% position, unchanged across quarters. This institutional vacuum speaks volumes about professional investors' assessment of the company's prospects.
The non-institutional holding has increased from 38.89% to 40.40% over the same period, absorbing the promoter dilution. However, retail investor interest in the absence of institutional participation often signals speculative trading rather than fundamental conviction, adding to the stock's volatility and downside risk.
Stock Performance: Severe Underperformance Across Timeframes
The stock's price performance has been dismal across most relevant timeframes. Over the past year, Everest Organics shares have declined 38.88%, underperforming the Sensex by 30.48 percentage points. The year-to-date performance shows a catastrophic 46.96% decline, versus the Sensex's 12.26% drop, representing negative alpha of 34.70 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +7.34% | -0.85% | +8.19% |
| 1 Month | -0.59% | -3.51% | +2.92% |
| 3 Months | -26.02% | -8.01% | -18.01% |
| 6 Months | -36.75% | -12.75% | -24.00% |
| YTD | -46.96% | -12.26% | -34.70% |
| 1 Year | -38.88% | -8.40% | -30.48% |
| 3 Years | +169.24% | +18.98% | +150.26% |
The six-month return of negative 36.75% and three-month decline of 26.02% indicate accelerating downward momentum. Only the very short-term periods (one week and one month) show positive relative performance, likely reflecting technical bounces rather than fundamental improvement.
Interestingly, longer-term returns paint a different picture. The three-year return of 169.24% and 10-year return of 931.92% suggest the stock has delivered exceptional performance over extended periods. However, these historical gains appear to have been driven by the pandemic-era pharmaceutical boom and subsequent speculation rather than sustainable business fundamentals, with recent performance reverting to reflect underlying operational weakness.
Investment Thesis: Deteriorating Fundamentals Trump Margin Recovery
The investment case for Everest Organics rests on several competing factors. The proprietary investment score stands at just 28 out of 100, firmly in "Strong Sell" territory. This assessment reflects the confluence of weak fundamentals, expensive valuation, bearish technical trends, and deteriorating financial performance.
The quarterly margin improvement in Q4 FY26, whilst noteworthy, appears insufficient to offset structural concerns. The company's inability to grow revenues over five years, persistent margin pressures evident in annual results, weak return on capital metrics, and elevated debt burden collectively suggest a business model under stress. The complete absence of institutional investor interest further validates concerns about long-term viability.
Key Strengths & Risk Factors
Key Strengths
- Operating Margin Recovery: Q4 FY26 operating margin of 13.74% represents highest level in recent quarters, suggesting potential for improved cost management
- Sequential Revenue Growth: 14.46% QoQ revenue growth in Q4 FY26 indicates improving demand environment
- No Promoter Pledging: Zero pledged shares demonstrates promoter financial stability
- Established Operations: Three-decade operating history since 1993 provides manufacturing expertise and customer relationships
- Sector Tailwinds: Indian pharmaceutical API sector benefiting from China+1 sourcing strategies globally
Key Risk Factors
- Zero Revenue Growth: Five-year sales CAGR of just 0.60% indicates inability to capture market opportunities
- Contracting Profitability: Operating profit declining at 12.16% annually over five years reflects structural margin pressure
- Weak Return Profile: ROE of 5.58% and ROCE of 1.12% (average) well below cost of capital
- Inadequate Interest Coverage: EBIT-to-interest ratio of 0.75x means operating profits fail to cover debt servicing costs
- High Debt Burden: Debt-to-EBITDA of 15.01x indicates excessive leverage relative to cash generation
- Institutional Exodus: Zero FII, MF, and insurance holdings signals professional investor rejection
- Expensive Valuation: P/E of 44.53x unjustified for weak growth and return profile
Outlook: What to Monitor Going Forward
Positive Catalysts
- Sustained operating margins above 12% for three consecutive quarters would indicate structural improvement
- Year-on-year revenue growth exceeding 15% for two consecutive quarters could signal market share gains
- Debt reduction bringing debt-to-EBITDA below 5x would improve financial flexibility
- Interest coverage ratio improving above 3x would ease debt servicing concerns
- Any institutional investor stake acquisition would validate improving fundamentals
Red Flags to Watch
- Further promoter stake reduction beyond 1% in any quarter would raise confidence concerns
- Operating margins reverting below 8% would confirm Q4 FY26 improvement as temporary
- Debt-to-equity ratio rising above 1.0x would indicate deteriorating financial position
- Interest coverage falling below 2.0x would create debt sustainability questions
- Continued absence of institutional buying despite valuation correction would confirm quality concerns
The path forward for Everest Organics requires demonstrating consistent revenue growth, sustainable margin improvement, and meaningful debt reduction. Without these fundamental shifts, the current valuation appears unjustified, and further downside remains likely as the market reprices the stock to reflect its weak competitive position and poor capital efficiency.
The Verdict: Exit Recommended on Fundamental Weakness
Score: 28/100
For Fresh Investors: Avoid initiating positions. The combination of zero revenue growth over five years, contracting operating profits, weak return on capital metrics, elevated debt burden, and expensive valuation creates an unfavourable risk-reward profile. The Q4 FY26 margin recovery appears tactical rather than strategic, insufficient to offset structural challenges.
For Existing Holders: Consider exiting positions on any technical bounces. The 38.88% decline over the past year reflects fundamental deterioration rather than temporary market weakness. With ROE of 5.58%, ROCE of 1.12%, and debt-to-EBITDA of 15.01x, the business destroys rather than creates shareholder value at current return levels. The complete absence of institutional interest validates concerns about long-term viability.
Fair Value Estimate: ₹125.00 (53% downside from current price of ₹268.30)
Rationale: Whilst the Q4 FY26 operating margin of 13.74% demonstrates potential, five years of sales stagnation, persistent profitability challenges, inadequate interest coverage, and expensive valuation multiples overwhelm this single positive data point. The pharmaceutical sector offers numerous higher-quality alternatives with superior growth trajectories, stronger return profiles, and more attractive valuations. Until Everest Organics demonstrates sustained revenue growth, meaningful debt reduction, and returns exceeding cost of capital, the investment case remains unconvincing.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed herein are subject to change without notice.
